32. Knab LM, Boller AM, Mahvi DM. Cholecystitis.
33. Sulzer JK, Ocuin LM. Cholangitis: causes, diagnosis, and management.
34. Center SA. Diseases of the gallbladder and biliary tree.
35. Wang HH, Liu M, Clegg DJ, Portincasa P, Wang DQ. New insights into the molecular mechanisms underlying effects of estrogen on cholesterol gallstone formation.
36. Dauer M, Lammert F. Mandatory and optional function tests for biliary disorders.
37. Behar J, Corazziari E, Guelrud M, Hogan W, Sherman S, Toouli J. Functional gallbladder and sphincter of oddi disorders.
38. Littlefield A, Lenahan C. Cholelithiasis: presentation and management.
39. Walters JR, Tasleem AM, Omer OS, Brydon WG, Dew T, le Roux CW. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis.
40. Redwan AA. Multidisciplinary approaches for management of postcholecystectomy problems (surgery, endoscopy, and percutaneous approaches).
41. Banks PA. Epidemiology, natural history, and predictors of disease outcome in acute and chronic pancreatitis.
42. Pezzilli R. Etiology of chronic pancreatitis: has it changed in the last decade?.
43. Kawa S, Hamano H, Ozaki Y, et al. Long-term follow-up of autoimmune pancreatitis: characteristics of chronic disease and recurrence.
44. Tezuka K, Makino T, Hirai I, Kimura W. Groove pancreatitis.
45. Dominguez-Munoz JE, Drewes AM, Lindkvist B, et al, for the HaPanEU/UEG Working Group. Recommendations from the United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis. Pancreatology. 2018
46. Owens SR, Greenson JK. The pathology of malabsorption: current concepts. Histopathology. 2007
1. Green PH, Lebwohl B, Greywoode R. Celiac disease.
2. Malik TF, Panuganti KK. Lactose intolerance.
3. Alyami J, Spiller RC, Marciani L. Magnetic resonance imaging to evaluate gastrointestinal function.
4. Vanuytsel T, Tack JF, Boeckxstaens GE. Treatment of abdominal pain in irritable bowel syndrome.
5. Sarna SK. Molecular, functional, and pharmacological targets for the development of gut promotility drugs.
6. Di Stefano M, Miceli E, Mazzocchi S, et al. Visceral hypersensitivity and intolerance symptoms in lactose malabsorption.
7. Toorenvliet B, Vellekoop A, Bakker R, et al. Clinical differentiation between acute appendicitis and acute mesenteric lymphadenitis in children.
8. Husebye E. Gastrointestinal motility disorders and bacterial overgrowth.
9. Kastin DA, Buchman AL. Malnutrition and gastrointestinal disease.
10. Saltzman JR, Russell RM. Nutritional consequences of intestinal bacterial overgrowth.
11. Vardy PA, Lebenthal E, Shwachman H. Intestinal lymphagiectasia: a reappraisal.
12. Nikaki K, Gupte GL. Assessment of intestinal malabsorption.
13. Quigley EMM. The spectrum of small intestinal bacterial overgrowth (SIBO).
14. Wei L, Ratnayake L, Phillips G, et al. Acid suppression medications and bacterial gastroenteritis: a population-based cohort study.
15. Garcia Rodriguez LA, Ruigomez A, Panes J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease.
16. Aune D, Chan DS, Lau R, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies.
17. Pala V, Sieri S, Berrino F, et al. Yogurt consumption and risk of colorectal cancer in the Italian European prospective investigation into cancer and nutrition cohort.
